openPR Logo
Press release

Associated Engineers Group acquires consultancy, Anabasis, to help clients deliver AI transformation

07-03-2023 02:46 PM CET | IT, New Media & Software

Press release from: Associated Engineers Group

Associated Engineers Group acquires consultancy, Anabasis,

MUNICH - June 30, 2023 - Associated Engineers Group (AEG), a renowned name in multi-disciplinary software engineering services, today unveiled its strategic alliance with Anabasis, a groundbreaking provider of AI and advanced analytics business transformation solutions.
With 50% to 60% of companies having embedded AI capabilities in their business processes, the ability to make the most of it and reach scale is vital to increase competitiveness.

This alliance merges AEG's extensive engineering capabilities with Anabasis's AI competencies and pioneering stance in data analytics. This robust amalgamation aims to offer clients an unprecedented boost in business performance and operational efficiencies through leveraging AI transformation.

"We at AEG are constantly on the lookout for progressive opportunities that will enhance our technological capacity and add more value to our clients," stated Daniel Ratke, CEO of AEG. "As an AI researcher myself, I see the transformative potential those applications can have for clients, but I also see them struggling to go beyond the proof-of-concept stage. Anabasis has experience in bridging that gap - and this is why it is such a strong fit with our own offer".

Anabasis, known for its unique capability to navigate the intricate journey of AI transformation, will enrich AEG's offerings by delivering comprehensive and targeted AI solutions to their clients. Anabasis's ability to develop scalable AI strategies will complement AEG's existing engineering services portfolio, ensuring clients can maximize the return on their AI investments.

In addition to enhancing the companies' service offerings, the partnership will also broaden their geographical footprint, establishing a global AI transformation network capable of serving a diverse range of sectors and markets. This initiative not only enriches the companies' service portfolio but also contributes to the evolution of innovative, accessible, and effective AI-driven solutions, benefiting businesses at different stages of AI adoption.

Münchner Str 25
85229 Markt Indersdorf
Germany
Press contact : Daniel Ratke, daniel.ratke@associatedengineersgroup.com

About Associated Engineers Group (AEG)
AEG is a globally recognized software engineering consultancy, providing companies with a single point of contact for their most challenging IT transformation. AEG originates from the DACH region and is expanding globally.

About Anabasis
Anabasis is a boutique firm specialized in AI transformation. Anabasis helps companies leverage the full potential of ML, GenAI and advanced analytics to deliver actual business impact. Anabasis is based in the US and has recently expanded in continental Europe.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Associated Engineers Group acquires consultancy, Anabasis, to help clients deliver AI transformation here

News-ID: 3109161 • Views:

More Releases for Anabasis

Retinitis Pigmentosa Clinical Trials Assessment 2024: FDA Approvals, Pipeline, T …
(Albany, USA) As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 30+ Retinitis Pigmentosa pipeline drugs in the therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Retinitis Pigmentosa Pipeline Insight, 2024" report by DelveInsight provides a
Retinitis Pigmentosa Pipeline Analysis 2024: Clinical Trials, Therapies, Compani …
(Albany, USA) As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 30+ Retinitis Pigmentosa pipeline drugs in the therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Retinitis Pigmentosa Pipeline Insight, 2024" report by DelveInsight provides a
Retinitis Pigmentosa Pipeline Assessment (2023) Covering Clinical Trials, Emergi …
As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 30+ pipeline drugs in the Retinitis Pigmentosa therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Retinitis Pigmentosa Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis
Retinitis Pigmentosa Market to Register Stunning Growth During the Forecast Peri …
As per DelveInsight, the Retinitis Pigmentosa Market is anticipated to evolve immensely in the coming years owing to the expected launch of potential therapies, along with increasing awareness and the rise in the number of cases of Retinitis Pigmentosa in the 7MM. DelveInsight's "Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Retinitis Pigmentosa Market
Retinitis Pigmentosa Pipeline Assessment (2023 Updates) | In-depth Insights into …
As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 30+ pipeline drugs in the Retinitis Pigmentosa therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Retinitis Pigmentosa Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis